Skip to main content
. 2012 Jun 6;4(8):705–718. doi: 10.1002/emmm.201101105

Figure 4. Bi-allelic Igf2 expression accelerates tumour formation in p53+/− female mice, irrespective of strain.

Figure 4

  1. Survival of B6 H19−m/+p, p53+/− mice was significantly reduced compared to p53+/− mice (p = 0.0065, log-rank test). Due to accelerated tumour latency the humane end point was brought forward to 400 days.
  2. Survival of 129 H19−m/+p, p53+/− mice was significantly reduced compared to Igf2+/−p, p53+/− (p = 0.0001), Igf2+m/+p, p53+/− (p = 0.008) and H19+m/+p, p53+/− mice (p = 0.036, log-rank test).
  3. Survival of F2 hybrid H19−m/+p, p53+/− mice was significantly reduced compared to Igf2+m/−p, p53+/− (p = 0.0008), Igf2+m/+p, p53+/− (p = 0.0017) or H19+m/+p, p53+/− mice (p = 0.0018, log-rank test).
  4. Tumour latency in B6 H19−m/+p, p53+/− female mice was significantly reduced compared to H19−m/+p, p53+/− males and p53+/− females and male mice (p < 0.0007, log-rank test).
  5. B6 H19−m/+p, p53+/− mice had significantly more solid tumours (carcinomas and sarcomas) and fewer lymphomas than B6 H19+m/+p, p53+/− mice (p = 0.037, Fisher's exact test).